Condition
Any Solid Tumors Progressed After a Prior Immunotherapy
Total Trials
1
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Vmd928 100 Mg Tablet
Related Conditions
Often studied with 20 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 1/2 (1)
Trial Status
Recruiting1
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Vmd928 100 Mg Tablet1
- Vmd928 Tablet And Pembrolizumab 200 Mg1
Active Sponsors
- VM Oncology, LLC1
Related Conditions
- Head And Neck Squamous Cell Carcinoma Hnscc1
- Head And Neck Cancers Nasopharynx1
- Lung Cancer1
- Lung Cancer Locally Advanced Or Metastatic1
- Head And Neck Cancers Lip1